B Braun Medical Company Profile
✉ Email this page to a colleague
What is the competitive landscape for B BRAUN MEDICAL
B BRAUN MEDICAL has sixteen approved drugs.
There are three US patents protecting B BRAUN MEDICAL drugs.
There are fifty patent family members on B BRAUN MEDICAL drugs in twenty-nine countries and seventy-six supplementary protection certificates in sixteen countries.
Summary for B Braun Medical
| International Patents: | 50 |
| US Patents: | 3 |
| Tradenames: | 16 |
| Ingredients: | 15 |
| NDAs: | 16 |
Drugs and US Patents for B Braun Medical
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| B Braun Medical | LIDOCAINE HYDROCHLORIDE | lidocaine hydrochloride | INJECTABLE;INJECTION | 208474-001 | Aug 3, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ||||
| B Braun Medical | MEROPENEM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | meropenem | POWDER;INTRAVENOUS | 202106-002 | Apr 30, 2015 | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| B Braun Medical | PIPERACILLIN AND TAZOBACTAM AND SODIUM CHLORIDE IN DUPLEX CONTAINER | piperacillin sodium; tazobactam sodium | POWDER;INTRAVENOUS | 206056-002 | Apr 3, 2025 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for B Braun Medical Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Malaysia | 180957 | ⤷ Start Trial |
| Russian Federation | 2015128024 | ⤷ Start Trial |
| Poland | 1931304 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for B Braun Medical Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2603514 | 1990017-4 | Sweden | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF VABORBACTAM AND/OR SALT OR HYDRATE THEREOF, AND MEROPENEM AND/OR A SALT HYDRATE THEREOF, IN PARTICULAR MEROPENEM TRIHYDRATE.; REG. NO/DATE: EU/1/18/1334 20181122 |
| 0247633 | 62/1997 | Austria | ⤷ Start Trial | PRODUCT NAME: ATORVASTATIN CALCIUM; NAT. REGISTRATION NO/DATE: 1-21926, 1-21927, 1-21928 19970411; FIRST REGISTRATION: GB PL 00018/0240 - PL 00018/0242 19961107 |
| 3412676 | PA2020519 | Lithuania | ⤷ Start Trial | PRODUCT NAME: VABORBAKTAMO IR (ARBA) JO DRUSKOS, IR (ARBA) HIDRATO BEI MEROPENEMO IR (ARBA) JO DRUSKOS, IR (ARBA) HIDRATO, YPAC MEROPENEMO TRIHIDRATO, DERINYS; REGISTRATION NO/DATE: EU/1/18/1334 20181120 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
